SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) April 29, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On April 29, 1996 Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that clearance has been
granted by the Food and Drug Administration (FDA) to
market the Company's theraPORT Vascular Access System
(VAS). The Company submitted the 501(k) notification
to the FDA on January 22, 1996.
Through direct sales and distributors, BICO plans
to penetrate the established US port market which
supports approximately 150,000 such units a year at an
average cost of $375 per unit. Sales efforts in the
European market, which is very similar to the US, will
follow.
The device, which is implanted beneath the skin
with a catheter placed in a vein between it and the
heart, is an advantageous delivery system designed for
the patient whose medical care requires repeated
injections into veins over a long period of time. Such
continual injections can cause veins to shut down and
collapse. With the theraPORT in place, however,
multiple injections can be given without such vascular
trauma. If necessary to accommodate multiple drug
therapy with incompatible drugs, dual ports can be
implanted. Such devices are frequently used in cancer
drug therapy.
Biocontrol theraPORT is a high quality device
especially designed for safety and simplicity of use
thereby reducing complications associated with
implanted devices.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: April 29, 1996
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: April 29, 1996
